Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
(Date:8/28/2014)... Lawrence, MA (PRWEB) August 28, 2014 “This ... single test to screen from 0 to 150 ppb,” said ... test is a significant benefit to plant owners and USDA-GIPSA ... corn and other commodities. Testing can take place in a ... Not only can the plant test the feed and grain ...
(Date:8/28/2014)... important devices in spintronics, an electronic which is ... but also on their spin and the spin-related ... into magnetic signals and vice versa. Recently, the ... Institute of Physics at Johannes Gutenberg University Mainz ... and Japan, has for the first time realised ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... Neuftec,Limited, the proprietor of the original nano-particulate ... litigation in the,UK against Oxonica Energy Limited, a ... issued in the High Court of Justice, allege ... an injunction against Oxonica as well as damages,in ...
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... presenting at the Business Forum during BIO 2008,the ... held at the San Diego Convention Center from ... Senesco, will deliver the,Company,s corporate presentation on Wednesday, ...
... CHURCH, Va., June 12 CSC (NYSE: ... HealthTrio LLC to add portal and personal,health record ... and other payer clients. The added components include ... October 2007, FirstPortfolio provides users with a,collection of ...
Cached Biology Technology:Neuftec Issues Patent Infringement Proceedings in the UK Against Oxonica 2Senesco Technologies to Present at BIO 2008 Business Forum 2CSC and HealthTrio Team to Offer Portal and Personal Health Record Solution 2CSC and HealthTrio Team to Offer Portal and Personal Health Record Solution 3
(Date:8/31/2014)... is developing drugs that are highly effective against a ... patient. Such properties are directly related to the 3D ... have a shape that is perfectly complementary to a ... specificity. Publishing in Nature Chemistry , EPFL scientists ... the 3D structure of bioactive peptides and enhance their ...
(Date:8/31/2014)... Nature Climate Change , suggests that if current ... exceed, the global targets for total greenhouse gas (GHG) emissions ... all think carefully about the food we choose and its ... is just one of a number of actions that need ... there is enough food for all. , As populations ...
(Date:8/29/2014)... have made some surprising discoveries about the body,s ... virus (SIV), the team found that specialized cells ... responders to viral invasion and are the source ... interleukin-1 beta (IL-1β). , Though aimed at ... the gut epithelium that provides a barrier to ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4The early cost of HIV 2
... in billions, sometimes - like the snow bunting ... distances and enduring the most extreme frigid weather conditions. ... a stunning success of biological adaptation with Snow ... north as the Arctic Circle. Indeed, there is nothing ...
... be a household name even among farm families, but ... environmentally-friendly commercial biofuel feedstock, particularly for biodiesel and jet ... has just awarded $5.08 million to a team of ... Grain Science and Industry, Xiuzhi "Susan" Sun, to study ...
... coughs, soot or black carbon turns out to ... only to carbon dioxide, according to a four-year assessment by ... the soot particles in smoke and smog, contributes about twice ... the 2007 Intergovernmental Panel on Climate Change. "We were surprised ...
Cached Biology News:Novel approach to track migration of arctic-breeding avian species 2Novel approach to track migration of arctic-breeding avian species 3Researcher awarded $5.08 million to study oilseed camelina as biofuel feedstock 2Researcher awarded $5.08 million to study oilseed camelina as biofuel feedstock 3International study: Where there's smoke or smog, there's climate change 2International study: Where there's smoke or smog, there's climate change 3
... Glycosylation is a post-translational modification ... biological functions, including immune regulation, inflammation, ... Biotechnology has developed two lectin based ... and Wheat Germ Agglutinin (WGA), that ...
... carrier proteins to simplify the production ... Carrier Proteins are commonly used carriers ... heterobifunctional cross-linker (Sulfo-SMCC). This activation results ... Thus allowing the maleimide-activated carrier ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Cell Culture Flask, nontreated polystyrene...
Biology Products: